Soft-Tissue sarcoma in childhood and adolescence
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-002-0004-4.pdf
Reference26 articles.
1. Crist WM, Anderson JR, Meza JL, et al.: Intergroup Rhabdomyosarcoma Study IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19:3091–3102. This is the only randomized trial of cyclophosphamide versus ifosfamide and conventional versus hyperfractionated radiotherapy in pediatric RMS. It shows convincingly why VAC and chemoradiotherapy are the gold standard.
2. Baker KS, Anderson JR, Link MP, et al.: Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000, 18:2427–2434. This report suggests that the observed improvement in outcome in selected patients in the Intergroup study was related to increased alkylator dose intensity. However, it is not clear why some of the patients benefited and others did not.
3. Smith LM, Anderson JR, Qualman SJ, et al.: Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2001, 19:4058–4064. This 25-year experience with group II disease on IRS protocols shows that patients with embryonal RMS at favorable primary sites have the best outlook with modern therapy.
4. Sandler E, Lyden E, Ruymann F, et al.: Efficacy of ifosfamide and doxorubicin given as a phase II ‘window’ in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001, 37:442–448.
5. Breitfeld PP, Lyden E, Raney RB, et al.: Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatric Hematol Oncol 2001, 23:225–233. This randomized study demonstrates that ifosfamide plus etoposide is better than vincristine plus melphalan or ifosfamide plus doxorubicin, as reported by Sandler et al. [4]. The 3-year survival rate of 55% with ifosfamide plus etoposide is the best achieved yet in IRS studies with metastatic sarcoma.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pyroptosis-related genes prognostic model for predicting targeted therapy and immunotherapy response in soft tissue sarcoma;Frontiers in Pharmacology;2023-05-05
2. SKELETAL MALIGNANCIES AND RELATED DISORDERS;Textbook of Pediatric Rheumatology;2011
3. Pediatric extremity soft-tissue sarcomas: from diagnosis to surgical treatment;Current Orthopaedic Practice;2010-09
4. Weichteilsarkome;Uroonkologie;2009
5. Solide Tumoren;Therapie in der Kinder- und Jugendmedizin;2007
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3